PSMA and Beyond 2026 Conference Videos

Does FAP Have a Future? Pro / Con "Presentation" - Wolfgang Fendler & Lena Unterrainer

Initial Experience with APC3 "Presentation" - Philipp Backhaus

Optimization of Radioligand Chemistry "Presentation" - John Babich

Scaling Operations in Theranostics Clinical Research: Integrating Teams, Processes, and Regulatory Strategy "Presentation" - Stephanie Lira

Review of Recently Published Therapeutic Radiopharmaceuticals in Phase 1/2 Trials "Presentation" - Jeremie Calais

Approaches to Early-Stage Development and Dose Optimization "Presentation" - Anna Karmann

How PCWG4 Impacts Future Trials "Presentation" - Michael Morris

Incorporating PSMA PETs in Registrational Trials "Presentation" - Alicia Morgans

PSMA PET in Prostate Cancer Drug Development: Regulatory Challenges and Considerations "Presentation" - William Maguire

Monitoring the Marrow: Hematologic Toxicity in the Treatment of Advanced Prostate Cancer "Presentation" - Daniel Childs

Renal Toxicity Associated with PSMA Targeted Therapy "Presentation" - Ines Camille Azrour

The Expanding Theranostic Dream: From Hype to Hard Truths "Presentation" - Michael Hofman

DLL3: Does Target Expression Determine the Method of Targeting? "Presentation" - Rahul Aggarwal

PSMA and Other Targets in Antibody-Drug Conjugates & Bispecific T-cell Engages "Presentation" - Tanya Dorff

Modalities for Targeting the Cell Surface "Presentation" - Evan Yu

Cancer Therapy: Target, Modality, and Timing "Presentation" - Owen Witte

Predicting Radiation Resistance and Response with ctDNA "Presentation" - Sofie Tolmeijer

PSMA-RPT Resistance Mechanisms and Relapse "Presentation" - Christine Mona

Tests that Predict Radiation Sensitivity: Experience from Space Travel "Presentation" - Kevin Tabury

Does Dosimetry Matter? "Presentation" - Stephen Graves

Enhancing Radiosensitivity: Non-PARP DNA Repair Enzymes and Optimal Combinations with Radioligand Therapy "Presentation" - Jonathan Chou

How Important are Bystander Effects in Targeted Radionuclide Therapy? "Presentation" - Jean-Pierre Pouget

Are Alpha or Beta Particles Better for Immunogenic Priming? "Presentation" - Zachary Morris

Immunotherapy Beyond Checkpoint Inhibitors "Presentation" - Lawrence Fong

Lessons Learned from Radioligand Combinations "Presentation" - Shahneen Sandhu

How We Get to the Isotope "Presentation" - Jonathan Engle

Market and Raw Materials: "Stable Isotopes" Why are They so Important and Where to Find Them? "Presentation" - Nicolas Mario

The Theranostic Revolution: Innovation, Investment, and Implications "Presentation" - Germo Gericke

Does Dose Rate Matter? "Presentation" - Amanda Walker

Ac-PSMA: The Truth Should be Told! "Presentation" - Matthias Eiber

Is Astatine the Way to Go? "Presentation" - Tadashi Watabe

STAMPEDE2 PSMA-Lu Comparison "Presentation" - Nicholas James

Chemo versus PSMA RLT "Presentation" - François Bérnard

The PEACE-6-PR Trial "Presentation" - Désirée Deandreis

DORA and PEACE-3: Evolving Role of Ra-223 "Presentation" - Michael Morris

PSMAddition "Presentation" - Oliver Sartor

Does What We See on PSMA PET Matter? "Presentation" - Peter Choyke

SPECT Versus PET: Optimizing Response Biomarkers "Presentation" - Lisa Bodei

The Problem with Our Reports "Presentation" - Robert Reiter

Nuclear Medicine in Prostate Cancer Care "Presentation" - Johannes Czernin

Annual PSMA & Beyond Meeting Focuses on Clinical Trials, Biomarkers, and Unmet Needs - Thomas Hope & Jeremie Calais